Quality, credentials & accreditations


Meetings / Conferences Meet us at the IBC Drug Discovery and Development Conference Aug 4-7. Buzz Brown to speak Aug 6 at 10:10AM Ion Channels Play Key Role in R&D Genetic Enginering News article (Jun 1 2008 (Vol. 28, No. 11)). ChanTest profiled. Spotlight Paper Alfuzosin delays cardiac repolarization by a novel mechanism (2008) J Pharmacol Exp Ther. 324(2):427-433

Quality, credentials & accreditations

ChanTest is committed to delivering the highest quality services to our customers on time and at a cost-effective price. Our ion channel assays are continually tested to ensure the highest accuracy and precision. Quality control is exercised by our ion channel experts at each step of each assay from protocol development to data acquisition and analysis and assay reports.

ChanTest complies with U.S. FDA Good Laboratory Practices For Nonclinical Laboratory Studies (21 CFR Part 58), OECD’s Principles of Good Laboratory Practice and Japan’s MHLW Good Laboratory Practices. Nonclinical safety services are based on the ICH’s S7A Safety Pharmacology Studies for Human Pharmaceuticals and S7B Nonclinical Evaluation of the Potential for Delayed Repolarization (QT Interval Prolongation) by Human Pharmaceuticals.

ChanTest’s independent Quality Assurance Unit (QAU) maintains the highest standards for all nonclinical studies by staying current with regulatory trends and industry compliance standards through active membership in the national Society of Quality Assurance (SQA), MidWest SQA and Regulatory Affairs Professional Society (RAPS). A successful FDA audit attests to ChanTest’s commitment to GLP.